How Long Do Pharmaceutical Patents Last? (India and Global)

A pharmaceutical company files a patent on a new drug molecule. From that day, the clock starts. Twenty years later, the patent expires, and generic manufacturers can legally copy the drug , subject to applicable regulatory approvals.

That is the simple answer. It is also incomplete.

By the time that same drug reaches a pharmacy shelf, the clock has already been running for around eight to twelve years, through clinical trials, regulatory approvals, and safety studies. What looked like twenty years of protection on paper often turns out to be eight to twelve years of actual market exclusivity. Sometimes less.

And in India specifically, the rules work differently enough from the US and Europe that a company relying on the same patent strategy across all three markets can find itself with far less protection than it planned for.

This is what pharmaceutical patent duration actually looks like in practice, and where an IPR lawyer's job goes well beyond simply filing the application.

The 20-Year Term: What It Means and What It Does Not

Every country that is a signatory to the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) grants pharmaceutical patents a standard term of 20 years. India, the US, the EU, Canada, Japan: all follow this baseline.

The 20-year clock starts from the filing date of the patent application, not from the date the drug is approved for sale, not from the date it reaches patients, and not from the date the patent is actually granted. It starts the moment the application is filed.

Here is why that matters. A pharmaceutical company typically files a patent on a new molecule very early, often before clinical trials have even begun. The drug then spends the next eight to twelve years going through preclinical studies, Phase 1, Phase 2, and Phase 3 clinical trials, and then regulatory approval. All of that time comes out of the 20-year term.

So, a drug patented in 2005 and approved for sale in 2015 has roughly ten years of effective market exclusivity remaining, not twenty. And if the approval process ran longer than expected, that window shrinks further.

This gap between nominal patent life and actual commercial life is the central problem that pharmaceutical patent strategy is built around. Different countries have come up with different solutions to it, and India's solution looks very different from the US or Europe.

How the US Handles It: Patent Term Extensions

In the United States, the Hatch-Waxman Act of 1984 specifically addressed the problem of patent life lost to FDA approval delays. Under this law, pharmaceutical companies can apply for a Patent Term Extension (PTE) of up to five years to compensate for time spent in the regulatory approval process. The total patent term, including the extension, cannot exceed fourteen years from the date of FDA approval.

On top of this, the FDA grants additional market exclusivity periods that run separately from patent protection entirely. A brand-new drug compound gets five years of data exclusivity, meaning generic manufacturers cannot even submit an application to copy the drug during this period, regardless of whether a patent is in force. Orphan drugs, those developed for rare diseases, get seven years. Drugs that undergo new clinical studies get three additional years.

The practical result is that a drug in the US can have multiple overlapping layers of protection, the original patent, a term extension, and regulatory exclusivity, that together stretch effective market control well beyond what the 20-year term alone would provide.

How Europe Handles It: Supplementary Protection Certificates

The European Union uses a different mechanism called a Supplementary Protection Certificate (SPC). Like the US Patent Term Extension, an SPC compensates for time lost during regulatory approval, and can add up to five years of additional protection beyond the original patent term. An additional six months is available if the company conducts paediatric studies on the drug.

The maximum market exclusivity under an SPC is capped at fifteen years from the date the drug first received marketing authorisation in the EU.

India: The 20-Year Term With No Extensions

This is where India diverges significantly from the US and Europe.

Under Section 53 of the Patents Act, 1970, every patent in India, including pharmaceutical patents, lasts exactly 20 years from the filing date. There is no Patent Term Extension in India. No mechanism exists to add time back for years lost during clinical trials or regulatory approvals by the Central Drugs Standard Control Organisation (CDSCO).

That 20-year clock runs from the moment the application is filed, through every year of clinical development, and stops exactly two decades later with no adjustment. If a drug company files a patent in 2008 and receives CDSCO approval in 2018, they have ten years of market exclusivity left in India, with no way to extend it.

For pharmaceutical companies that file early to protect a promising molecule, this makes the effective commercial window in India shorter than in jurisdictions that provide patent term restoration or supplementary protection

Section 3(d): India's Unique Anti-Evergreening Rule

Globally, pharmaceutical companies use a strategy called evergreening to extend their effective patent protection beyond the original term. The idea is straightforward: once the core molecule patent is close to expiry, the company files new patents on slightly modified versions of the drug, such as a new salt form, a new polymorph, a new formulation, or a new dosage. Each new patent resets the clock on a variation of the original drug, keeping generic competition at bay even after the original patent expires.

In the US and EU, many of these secondary patents are routinely granted. In India, Section 3(d) of the Patents Act explicitly blocks most of them.

Section 3(d) states that a new form of a known substance, such as a new salt, ester, polymorph, or isomer, cannot be patented unless it shows significantly enhanced efficacy compared to the original known compound. Changing the physical form of a molecule without improving how well it actually works in a patient's body is not enough to get a new patent in India.

A concrete example makes this clearer. A pharmaceutical company has a cancer drug whose core molecule patent is expiring. In the US, the company successfully patents a new crystalline form (polymorph) of the same molecule and gets additional years of exclusivity. In India, that same polymorph patent application gets rejected under Section 3(d), because changing the crystal structure of the molecule did not make the drug work better for patients. The core molecule patent expires on schedule, and Indian generic manufacturers can legally produce the drug.

This is exactly what happened in the landmark Novartis AG vs. Union of India case in 2013. Novartis applied for a patent on a new crystalline form of Imatinib, the active ingredient in Gleevec, a cancer drug. The Supreme Court of India rejected the application, ruling that the new form did not show significantly enhanced efficacy over the original compound and therefore did not qualify for protection under Section 3(d). The case became a global reference point for how India's patent law treats secondary pharmaceutical patents differently from most other countries.

Compulsory Licensing: When the Government Steps In

India also has a provision that no Western pharmaceutical market uses with the same frequency: compulsory licensing.

Under Section 84 of the Patents Act, any person can apply to the government for a compulsory licence to manufacture a patented drug without the patent holder's permission, if any of three conditions is met: the drug is not available to the public at a reasonably affordable price, it is not available in sufficient quantity, or it is not being worked in India (meaning the patent holder is not manufacturing it locally).

In 2012, India granted its first compulsory licence to Natco Pharma to manufacture a generic version of Sorafenib, a kidney cancer drug patented by Bayer. Bayer's branded version was priced at approximately Rs 2.8 lakh per month. Natco's generic version was licensed at approximately Rs. 8,800 per month. The licence was granted on the grounds that the drug was not reasonably affordable and not available in sufficient quantities to patients who needed it.

Compulsory licensing does not end a patent. The original patent holder still holds the patent and typically receives a royalty payment. But it does mean that a valid, in-force patent can be overridden in specific public health circumstances, which is a risk that does not exist to the same degree in the US or EU.

Evergreening in India: What Is Still Possible

Section 3(d) closes off a significant portion of the evergreening strategies that work in other markets, but it does not eliminate all opportunities for patent protection.

Pharmaceutical companies may still obtain patents for genuinely novel and non-obvious inventions, such as innovative formulations, drug combinations, delivery systems, manufacturing processes, or dosage forms, provided they satisfy the requirements of the Patents Act. Patents on genuinely new methods of treatment, new combinations of existing drugs that show real clinical benefit, or new delivery mechanisms that meaningfully improve patient outcomes can still be filed and granted in India. The bar is simply higher than in the US or EU: a new patent in India needs to show a real improvement in how the drug works, not just a structural variation of the molecule.

For pharmaceutical companies planning their India patent strategy, this means the portfolio that protects a drug in the US does not automatically protect it in India. Each secondary patent needs to be separately evaluated for whether it can clear the Section 3(d) threshold.

Patent Term vs. Market Exclusivity: The Distinction That Matters

These two terms are often used interchangeably, but they are different things.

The patent term is the legal duration of the patent itself. In India, that is 20 years from filing, with no extensions.

Market exclusivity is how long the patent holder actually has the market to itself in practice, which depends on when competitors enter, whether any oppositions delay the patent grant, and whether compulsory licences are issued.

A patent that is filed early, gets stuck in opposition proceedings for several years, and is then subject to a compulsory licence application may have a nominal 20-year term but a real commercial window of far less.

Where Patent Strategy Actually Happens

Filing a pharmaceutical patent is the starting point. The decisions that determine how much of that 20-year term actually translates into enforceable market exclusivity, how early to file, which secondary patents can survive Section 3(d), how to respond to pre-grant or post-grant oppositions, and how to structure a patent portfolio across multiple markets, are what an experienced IPR lawyer works through with pharmaceutical clients over the life of the product.

M & P IP Protectors advises pharmaceutical and biotech companies on patent filing, opposition handling, and lifecycle strategy in India, working through the specific constraints of Indian patent law rather than applying a global template that does not account for Section 3(d) or the absence of term extensions.

If you are planning a pharmaceutical patent filing in India or reviewing an existing portfolio for coverage gaps, schedule a consultation with our patent attorneys to assess where your protection actually stands.